EGFR and colorectal carcinoma: A meta-analysis study conducted by Holch et al. showed variable responses toward anti-EGFR therapy based on the genetic profile and anatomical location of metastatic CRC [33], with CRC mutations occurring on the right side having poorer response to anti-EGFR therapy in contrast to LCRC.